Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in diagnostics and life sciences. In 2013, Anteo achieved solid commercial progress including partnership agreements that are enhancing the prospects of becoming cash flow positive in 2014. Anteo is now focused on advancing near-term opportunities to generate licensing fees and royalties from Mix&Go and expanding into the large market for bioseparations.

1. Anteo Diagnostics Limited (ASX:ADO)
ASX Spotlight Series - New York and London
February/March 2014
Presented by Dr. Geoff Cumming
Managing Director & CEO
“Solid commercial progress and growing revenue streams achieved in 2013 enhance
Anteo’s prospects of becoming cash flow positive in CY2014”

2. Company Snapshot
Anteo Diagnostics Limited (“Anteo”) is an
Australian biotechnology company that
develops, manufactures and
commercialises proprietary surface
coatings for the global healthcare
industry.
Corporate Snapshot
ADO
Cash
$7.1M
Market Cap.
$134
52 week high
$0.20
52 week low
Major Shareholders
ASX
$0.05
Shares on issue
814.4M
First Cape Mgt Pty Ltd
9.52%
Shareholders
4,414
Austcorp 190 Pty Ltd
4.05%
Top 20
31%
Directors/staff
17%
Nimrod Finance Ltd
2.44%
Board of Directors
Executive Team
Mr. Mark Bouris – Non-Executive Chairman
Dr. Geoff Cumming – Chief Executive Officer
Ms. Sandra (Sam) Andersen – Non-Executive Director
Mr. Richard Martin – Executive Director
Dr. John Hurrell – Non-Executive Director
Dr. Geoff Cumming – Chief Executive Officer
Dr. Joe Maeji – Chief Scientific Officer
Mr. Richard Martin – Chief Financial Officer
Dr. Tina Baumgartner – VP Business Development & Marketing
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
2

3. Recent Highlights
Solid commercial progress and growing revenue streams achieved in 2013…
 Feb 2013
Sales partnership agreement with U.S. based One World Lab
 May 2013
Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America
 June 2013
Feasibility agreement with global healthcare company for development of Point of Care device
 June 2013
Granted European Patent on Mix&Go
 July 2013
Received a 2-year $1.7M grant with Commercialisation Australia from April 2013
 November 2013
Heads of Terms signed with BBI Solutions, a global leader in immunoassay development and
manufacturing services
…enhancing the company’s prospects of becoming cash flow positive in CY2014
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
3

4. Mix&Go - Universal Surface Coating
Mix&Go: A Game Changing Product with emerging revenue streams and significant
growth potential
Mix&Go is a specialized universal “glue”:
•
uniquely suited for applications in
diagnostics and life sciences
Mix&Go is applicable to numerous other
large healthcare related segments, e.g.:
•
Separation of proteins and cells
•
Forms ultrathin (< 1nm) layers that bond
strongly
•
Drug discovery and
development
•
Is gentle and does not damage the activity
of fragile biomolecules
•
Medical devices
•
Drug delivery
•
Improves pathology tests  earlier
disease detection
•
Reduces cost of test development and
manufacture (faster/less Ab required)
Mix&Go is well suited to be the “glue” of choice in a variety of applications and industries outside of
healthcare, e.g. Resources and Cleantech
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
4

5. Game Changing Products for Life Sciences
Orientation is
random
3D structure is
damaged
Proprietary solution:
metal polymers
Undamaged,
oriented
Characteristics
Characteristics
Benefits
Vast majority of proteins are nonfunctional
Undamaged, fully functional proteins on
surface
Increased performance
Less non-specific binding
Improved protein stability
More protein (Ab) needed
Less protein and/or beads required
Reduced cost
Saves valuable, expensive proteins
Complicated, time-consuming procedures
Easy and fast to use and manufacture
Improves efficiency
Simpler test procedures
Manufacturing faster, easier, more scalable
Improved reproducibility
Improved accuracy with improved %CV
Expert knowledge needed
Lower sensitivity, LOD, dynamic range
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
5

6. Value Creation and Capture
Large global healthcare markets underpin revenue growth potential
Anteo is targeting large and growing healthcare sectors with Mix&Go. The compelling market opportunities are:
• Laboratory Diagnostics: Encompassing the global IVD market valued at $44 billion in 2011, including the
immunoassay sector at $8.8 billion
• Point-of-Care: Expected size of market by 2017 is $38 billion
• Rapid Test Products: Valued at $3.7 billion in 2012
• Life Science R&D: A very large and diverse $1 billion sector
• Bioseparations: Encompassing protein and protein drug manufacturing sector valued at up to $5 billion
Anteo has multiple and recurring revenue streams including:
• Development Fees: From $250,000+ per full-time employee
• License Fees: From $150,000 + p.a
• Ongoing Royalties: On sales from products containing Mix&Go
Potential royalty earnings vary depending on the size of the company and the degree of benefit Mix&Go can bring.
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
6

7. Milestones 2014
2014
2015
Advancing near-term value accretive opportunities that will translate quickly into revenue….




License and supply agreement with global point-of-care company
Extension of agreement with global lateral flow company
Anteo Mix&Go (AMG) bead and plate products launched in Australia
Pipeline of additional, unique, value-added solutions for the R&D space realised with partners worldwide
Anteo is commencing its next phase of product development
Anteo filed two sets of patent applications in August 2013. These patents will complement the existing Mix&Go patent
portfolio, and expand the protected areas of application to bioseparations, drug screening, drug delivery and areas
outside the health care industry, e.g., in clean tech and resources sectors.
Anteo has 4 advanced projects and ongoing pipeline development. We expect to close
deals with 10 or more medium to large companies during next 4 years.
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
7

8. Bioseparation – Anteo’s Next Opportunity
Current Approach
Paradigm Shift
Chromatography:
•
Time consuming
•
Expensive
•
Hard to automate
•
Capacity constraints
With Mix&Go magnetic separation can become
reality
•
Technically superior solution
•
Economically advantageous
Alternative
Large Opportunities
Magnetic separation:
•
Technically superior
•
Currently unaffordable
•
•
•
Protein and protein drug manufacturing: $35B
Vaccine manufacturing: $620M in 2015
Stem cell therapy market,: $1 B, CAGR 30%
Leverage Mix&Go in bioseparations to create
significant long-term revenue streams for Anteo
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
8

9. Anteo’s Opportunities
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
9

10. Anteo’s Keypoints
 Mix&Go is a proprietary platform technology with broad applicability in
diagnostics, life sciences, bioseparations and beyond
 Mix&Go is proven licensed and gaining significant traction in commercial
markets
 Mix&Go success means Anteo is becoming cash flow positive
 Strong near term value drivers
 Focus on diagnostics and life sciences with expansion into bioseparations
provides Anteo significant revenue opportunities
 Strong leadership - Board and management team in place to drive growth
 Global team, resources and network to capitalise on growth opportunity
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
10

11. Contact Information
Thank you very much for your interest in Anteo Diagnostics
For more information please contact:
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
11

12. Forward Looking Statement
The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been
prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.
Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements
made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the
Company's website for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been
independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may
prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties
and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results
to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown
risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and
beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this
presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014
12